Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
London, UK – 31 Aug 2015: Respiratory infection is associated with a four-fold increased risk of in-hospital cardiovascular mortality after acute myocardial infarction (AMI), according to research presented at ESC Congress today by Dr Catarina Quina-Rodrigues, a cardiologist at Hospital de Braga in Portugal.1 The findings highlight the importance of diagnostic alertness for respiratory infections in AMI patients so that therapeutic measures can be promptly taken.
EMBARGO : 31 August 2015 at 13:00 BST
“Cardiovascular disease remains the leading cause of death in Europe and around the world,” said Dr Quina-Rodrigues. “Due to important advances in primary prevention, patients admitted with MI are frequently older and often have a higher comorbidity load. Interestingly, there is a significant overlap between risk factor profiles for the development of AMI and respiratory infection (RI), namely older age, diabetes and smoking, therefore increasing the susceptibility of this population to infectious complications.”Epidemiological data suggests that RI can trigger the development of adverse cardiac events, namely AMI. This could be due to increased cardiac workload and the release of proinflammatory mediators that promote endothelial dysfunction and hasten atherosclerotic plaque instability and rupture. Evidence from human and animal studies supports the reverse association, with a higher susceptibility to bacterial infection after AMI or during an acute heart failure episode.2The current study aimed to evaluate the impact of the development of respiratory infection on in-hospital cardiovascular mortality in patients admitted for AMI. The researchers retrospectively analysed data from 1 907 patients admitted with AMI over a four year period. Respiratory infection was diagnosed based on chest X-ray, and clinical and analytical data. Clinical and laboratory features, treatment and adverse events were compared in patients with and without RI.During the study period, 117 patients developed RI (6%). RI development was associated with older age, higher diabetes prevalence and a more severe clinical presentation. The development of RI was associated with a worse disease course, longer length of stay, higher Killip Class,3 and higher incidence of malignant arrhythmias, ischaemic stroke and reinfarction along with more frequent need for transfusional, circulatory and respiratory support.The researchers found that patients with RI had a 6.12 times higher in-hospital cardiovascular mortality than those without RI (95% confidence interval [CI]=3.34-11.21, p<0.001). After adjusting for classical risk factors for cardiovascular mortality (such as age, gender, systolic blood pressure, renal function, NT-proBNP), RI remained an independent predictor of in-hospital cardiovascular mortality with an adjusted odds ratio of 3.93 (95% CI=1.704-9.074, p=0.001).“We found that patients with a respiratory infection have a four-fold higher risk of in-hospital mortality from cardiovascular disease after acute myocardial infarction than those without a respiratory infection,” said Dr Quina-Rodrigues. “These results strengthen the importance of timely recognition of infectious complications in MI patients, which can be challenging given the overlap of RI and heart failure symptoms.”She concluded: “Respiratory infection recognition in myocardial infarction patients should promote the rapid institution of targeted therapy in order to minimise the deleterious effects of infection on myocardial function and recovery.”ENDS
1Dr Quina-Rodrigues will present the abstract ‘Respiratory infection following acute myocardial infarction is an independent predictor of in-hospital cardiovascular mortality’ during:• The press conference ‘Life Threatening Scenarios’ on Monday 31 August at 13:00• Poster session 7: Inflammation and immunity II on Tuesday 1 September at 14:00 in the Poster Area 2In this case increased intestinal permeability to bacteria, driven by increased capillary hydrostatic pressures, has been proposed to cause transient bacteremia and proinflammatory activation. The increased release of proinflammatory mediators can in turn have negative effects on cardiac function, the myocardial repair/recovery process and outcome.3Killip Class is used to risk stratify patients after AMI. Risk of death is lowest in Killip Class I and highest in Killip Class IV.
SOURCES OF FUNDING: None.
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved